An observational study in Insufficient Breast Milk Syndrome and Premature Birth, sponsored by Centro Hospitalar de Lisboa Central. Enrolling by invitation at 1 site in Portugal. Open to female participants. Per ClinicalTrials.gov, last updated 2025-03-18.
Sponsored by Centro Hospitalar de Lisboa Central · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Maintaining milk production in lactating mothers who have delivered prematurely can be a challenge. In these cases, domperidone has been the most commonly used pharmacologic galactagogue. There are several studies on the effect of this drug on the volume of milk produced, but data on its effect on the macronutrient and energy content is scarce. The mid-infrared spectroscopy is a convenient validated method to assess human milk macronutrient and energy content because it requires little training for its operation and a small volume of milk. This study aims to determine the effect of domperidone on the macronutrient and energy content of milk from women who have delivered prematurely, and to compare the results obtained with those reported using reference methods for this analysis.
Study design: This is a single-center observational study based on a convenience cohort of lactating women who have delivered before 37 weeks gestation.
Study period: A consecutive recruitment of participants will be scheduled over 12 months (from February 2, 2025), according to the availability of the observer (M.C.) in charge of the analysis of breast milk in the unit, performed weekly on a routine basis, in order to be fortified if necessary (Cardoso 2023).
Settings: Neonatal Intensive Care Unit (NICU) and Human Milk Bank at Maternidade Dr. Alfredo da Costa, Unidade Local de Saúde São José, Lisbon.
Product to be analyzed: breast milk Demographic variables: Retrieved demographic and clinical variables will include participant age and gestational age at delivery, reported body weight and height closer to the beginning of pregnancy, type of delivery (vaginal or cesarean), parity, pathological conditions during pregnancy (hypertension, pre-eclampsia, gestational diabetes, and intrauterine growth restriction), date of initiation of domperidone, whether it was prescribed by a health professional or on their own initiative, domperidone dosage, and days of lactation at the time of breast milk analyses.
Method of collection and analysis of breast milk: as described in previous studies (Macedo MHNP 2018, Cardoso 2021), mothers will be asked to save milk collected through 24 hours in the same container, in order to minimize daily variability of breast milk composition. The breast milk macronutrient and energy content will be analyzed using the Miris Human Milk analyzer (Miris AB, Uppsala, Sweden).
Measured breast milk macronutrient and energy content: The breast milk macronutrient and energy content will be analyzed using the Miris® Human Milk analyzer (Miris AB, Uppsala, Sweden) following the milk collection and analysis procedures described (Czosnykowska-Łukacka 2018, Macedo MHNP 2018, Cardoso 2021). Before each use, the analyzer will be calibrated using the standard calibration solution (Quan 2020). The breast milk composition will be expressed in densities: Kcal/dL of energy and g/dL of fat, total and true protein, carbohydrates, and ashes (Macedo MHNP 2018, Cardoso 2021).
According to the Unit's routine, the milk of mothers of preterm infants, particularly very preterm infants, is analyzed weekly to assess the need for fortification (Cardoso 2023).
Within-subject differences in the macronutrient and energy milk content will be determined by comparing the value of each parameter (total and true protein, total fat, total carbohydrates and energy) in the last measurement before starting domperidone (M0) with the respective value 14 days after starting (M14).
Estimate of sample size: The study sample size was calculated to detect an effect size of 0.35 between pairs of breastmilk content in total protein, with a significance level of 0.05, and an 80% power; thus, a required sample of 81 infants (67 participants more 20% for drop out) was estimated.
Statistical Analyses Mean of breastmilk macronutrient content will be compared by paired-t test for normal distributed differences or Wilcoxon test if non-normal distributed differences.
2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.
This study's planned enrollment of 81 is below the median of 120 across 809 observational studies indexed under Premature Birth.
Browse Premature Birth studies →Centro Hospitalar de Lisboa Central is the lead sponsor of 16 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Lactating women who have delivered prematurely using domperidone as a galactagogue
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Breast milk macronutrient and energy content assessed by mid-infrared spectroscopy method
Dietary Supplement: Test group
Breast milk macronutrient and energy content assessed by Kjeldahl and Röse-Gottlib methods
Dietary Supplement: Reference group
In this group the Miris Human Milk analyzer will be used, consisting of a real-time mid-infrared technology that directly measures the concentration of protein, fat and carbohydrate, and calculates the energy content based on direct measurements.
In this group the Kjeldahl method will be used to assess total nitrogen concentration, the Röse-Gottlib method to assess fat concentration, and energy and carbohydrate concentration will be calculated by differences. Kjeldahl and the Röse-Gottlib are considered reference methods
True protein content
Within-subject difference of breastmilk content in true protein (protein with nutritional value)
Time frame: Between the last assessment before starting domperidone and the assessment 14 days after starting domperidone. The difference value between 14 days after domperidone and before starting it, expressed as percentage of the value before starting domperidone
Total protein
Within-subject difference of breastmilk content in total protein
Time frame: Between the last assessment before starting domperidone and the assessment 14 days after starting domperidone. The difference value between 14 days after domperidone and before starting it, expressed as percentage of the value before starting domperidone
Fat
Within-subject difference of breastmilk content in fat
Time frame: Between the last assessment before starting domperidone and the assessment 14 days after starting domperidone. The difference value between 14 days after domperidone and before starting it, expressed as percentage of the value before starting domperidone
Carbohydrate
Within-subject difference of breastmilk content in carbohydrate
Time frame: Between the last assessment before starting domperidone and the assessment 14 days after starting domperidone. The difference value between 14 days after domperidone and before starting it, expressed as percentage of the value before starting domperidone
Total energy content
Within-subject difference of breastmilk content in total energy
Time frame: Between the last assessment before starting domperidone and the assessment 14 days after starting domperidone. The difference value between 14 days after domperidone and before starting it, expressed as percentage of the value before starting domperidone
Percentage differences for total protein
The mean of the percentage differences for total protein obtained in the test group will be compared with the correspondent value obtained in the reference group.
Time frame: Between the last assessment before starting domperidone and the assessment 14 days after starting domperidone. The difference value between 14 days after domperidone and before starting it, expressed as percentage of the value before starting domperidone
Percentage differences for true protein
7The mean of the percentage differences for true protein obtained in the test group will be compared with the correspondent value obtained in the reference group
Time frame: Between the last assessment before starting domperidone and the assessment 14 days after starting domperidone. The difference value between 14 days after domperidone and before starting it, expressed as percentage of the value before starting domperidone
Percentage differences for fat
The mean of the percentage differences for fat obtained in the test group will be compared with the correspondent value obtained in the reference group
Time frame: Between the last assessment before starting domperidone and the assessment 14 days after starting domperidone. The difference value between 14 days after domperidone and before starting it, expressed as percentage of the value before starting domperidone
Percentage differences for carbohydrate
The mean of the percentage differences for carbohydrate obtained in the test group will be compared with the correspondent value obtained in the reference group
Time frame: Between the last assessment before starting domperidone and the assessment 14 days after starting domperidone. The difference value between 14 days after domperidone and before starting it, expressed as percentage of the value before starting domperidone
Percentage differences for total energy
The mean of the percentage differences for total energy obtained in the test group will be compared with the correspondent value obtained in the reference group
Time frame: Between the last assessment before starting domperidone and the assessment 14 days after starting domperidone. The difference value between 14 days after domperidone and before starting it, expressed as percentage of the value before starting domperidone
Plan to share: Undecided
Started Jan 2025 (actual). Primary completion is estimated for Jul 2025, 6 months after the start.
Of 373 non-industry observational studies under Premature Birth, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 63. This study's planned 6 months is below that.
Counting every sponsor, half of 388 studies reached it within 35 months; a quarter within 19 and three quarters within 61.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centro Hospitalar de Lisboa Central